Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
7.25 ^USD	+3.13%		+4.32%	-18.17%

09/05	Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/04	Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	CI

Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 10, 2022 at 05:41 pm IST

Aura Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 15.9 million compared to USD 8.84 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 28.33 a year ago.
For the nine months, net loss was USD 42.2 million compared to USD 23.62 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 77.93 a year ago.

Latest news about Aura Biosciences, Inc.

Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	16/04	CI
Aura Biosciences Shares Rise Following Q4 Results	27/03	MT
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
BTIG Cuts Aura Biosciences' Price Target to $21 From $38, Keeps Buy Rating	08/12	MT
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	08/12	MT
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	16/11	DJ
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	10/11	MT
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma	07/11	CI
Aura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-Sar	07/11	DJ
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023	01/23/01	CI
Aura Biosciences Insider Bought Shares Worth $168,175, According to a Recent SEC Filing	06/23/06	MT
Aura Biosciences Appoints New Chief Medical Officer	03/23/03	MT
Aura Biosciences, Inc. Announces Executive Changes	03/23/03	CI
Aura Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Scotiabank Starts Aura Biosciences at Sector Outperform With $23 Price Target	27/23/27	MT
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell Small Cap Comp Value Index	23/23/23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell Microcap Value Index	23/23/23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 3000E Value Index	23/23/23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 2500 Value Index	23/23/23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 3000 Value Index	23/23/23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 2000 Value Index	23/23/23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell Microcap Growth Index	23/23/23	CI

Chart Aura Biosciences, Inc.

Duration

Period

More charts

Company Profile

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.

Sector

Biotechnology & Medical Research

Calendar

11:30pm - Investor Meeting - Key Opinion Leader

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.25 USD

Average target price

19.8 USD

Spread / Average Target

+173.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AURA BIOSCIENCES, INC.	-18.17%	35Cr
MODERNA, INC.	+54.05%	6.39TCr
IQVIA HOLDINGS INC.	-2.02%	4.18TCr
LONZA GROUP AG	+40.01%	4.05TCr
CELLTRION, INC.	-10.22%	2.72TCr
ICON PUBLIC LIMITED COMPANY	+13.42%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	1.87TCr
BIO-TECHNE CORPORATION	+2.89%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+22.40%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.49%	1.21TCr

Other Biotechnology & Medical Research